High-frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-daily Regimen
Dastjerdi, Mohammad H
MetadataShow full item record
CitationDastjerdi, Mohammad H, Pedram Hamrah, and Reza Dana. 2009. “High-Frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-Daily Regimen.” Cornea 28 (10) (December): 1091–1096. doi:10.1097/ico.0b013e3181a16472.
The purpose of this study was to report the efficacy of topical cyclosporine 0.05% at a frequency of 3 to 4 times daily in severe dry eye disease.
We retrospectively identified a cohort of patients with severe dry eye disease who had shown inadequate response to at least a 4-month course of treatment with twice-daily use of topical cyclosporine 0.05% but who showed significant improvement to more frequent dosing.
Twenty-two patients, including 13 patients with ocular graft versus host disease and 9 patients with primary or secondary Sjögren’s syndrome, were included. After a minimum of a 2-month course of treatment with more frequent dosing of cyclosporine 0.05% (3 times a day in 7 patients and 4 times a day in 15 patients), overall dry eye symptoms were improved in 15 (68.2%) patients (9 patients with ocular graft versus host disease and 6 patients with Sjögren’s syndrome). Mean corneal fluorescein staining scores (National Eye Institute scale of 0–15) improved (decreased) from the baseline (precyclosporine use) by −3.5 (range, 0 to −7) in patients with ocular graft versus host disease (P ≤ 0.0008) and −2.8 (range, 0 to −5) in patients with Sjögren’s syndrome (P ≤ 0.001). After treatment with high-frequency use of cyclosporine 0.05%, the global physician assessment of dry eye status was favorable (improved) in 16 (72.7%) patients. Three (13.6%) patients reported new-onset symptoms of burning or irritation with the use of high-frequency dosing of topical cyclosporine. No other associated adverse effect was reported.
These data suggest that patients with severe dry eye may require more frequent dosing of topical cyclosporine 0.05% than twice daily.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34744155
- HMS Scholarly Articles